Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma

Table 1 Baseline demographics pancreatic adenocarcinoma (n = 97) n (%)

Characteristic	Mean ± SEM
Age	66 ± 0.9
Weight at dx (lbs)	80. 4 ± 1.7
LMR	2.36 ± 0.16
CA 19-9	17030.2 ± 8861
CEA	960 ± 657
Tumor size (cm)	4.13 ± 0.2
WBC	9.1 ± 0.5
Platelets	276.8 ± 12.2
ALC K/μL	1.5 ± 0.07
AMC K/μL	0.74 ± 0.03
Race
White	64 (66)
Black	29 (30)
Other	4 (4)
Location
Head	64 (71)
Body	10 (11)
Tail	16 (18)
Stage
I	1 (1)
II	23 (24)
III	14 (14)
IV	59 (61)
Treatment
Surgery	22 (23)
Stent	38 (39)
Any chemo/rad	44 (45)
Palliative chemotherapy	36 (37)
Neoadjuvant chemotherapy	3 (3)
Adjuvant chemotherapy	10 (10)
Risk factors
Alcohol	53 (55)
Tobacco	76 (78)

Table 2 Clinical variables in patients with high and low lymphocyte-to-monocyte ratio

	LMR ≤ 2.05 (n = 50)	LMR > 2.05 (n = 43)	P value
Chemoradiation	20	21	0.4
Surgery	7	14	0.05
Stent	19	16	1.0
Stage			0.2
Stage 1	0	1
Stage 2	8	14
Stage 3	8	5
Stage 4	34	23
Location			0.4
Head	35	27
Body	3	6
Tail	9	6
Race			0.05
White	36	25
Black	11	18
Other	3	0
CEA (± SEM)	1075 ± 1041	884 ± 868	0.9
CA 19-9 (± SEM)	24957 ± 17470	10162 ± 3448	0.4
Age (± SEM)	66.6 ± 1.2	65.3 ± 1.4	0.5
Weight (± SEM)	79.3 ± 2.2	82.2 ± 2.5	0.4
Alcohol	27	24	1.0
Tobacco	38	34	0.8

LMR: Lymphocyte-to-monocyte ratio.